

April 5, 2022

Bobby Gaspar, M.D., Ph.D.  
Chief Executive Officer  
Orchard Therapeutics plc  
108 Cannon Street  
London EC4N 6EU  
United Kingdom

Therapeutics plc  
Statement on Form S-3  
2022

Re: Orchard  
Registration  
Filed March 30,  
File No. 333-263967

Dear Dr. Gaspar:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Hagius at 202-551-7967 with any questions.

Please contact Dillon

Sincerely,

Division of Corporation Finance

Office of Life Sciences

cc:

Benjamin K Marsh